Lead Product(s): Squalene
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Queensland
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 12, 2020
CSL said it will provide technical expertise and a donation of MF59 to the University of Queensland’s preclinical development program.